CA
NZ
UK
AU
IND
US
Adam D. Portnoy, a director of Industrial Logistics Properties Trust (NASDAQ:ILPT), filed a Form 4 on September 21, 2026, reporting a share disposition on September 17, 2026, related to tax withholding upon a vesting event.
Tiffany R. Sy, CFO and Treasurer of Industrial Logistics Properties Trust, filed a Form 4 on September 21, 2026, reporting a share disposition on September 17, 2026, in connection with a tax withholding event at vesting.
Chris P. Gropp, Senior Vice President and CFO of PHINIA INC. (NYSE:PHIN), filed a Form 4 on September 21, 2026, reporting the acquisition of shares of common stock on September 18, 2026, through automatic dividend reinvestment on outstanding restricted stock.
Kendra Adams, Chief Financial Officer of C4 Therapeutics, Inc., filed a Statement of Changes in Beneficial Ownership on September 21, 2026, reporting two transactions in the company's common stock dated September 18, 2026.
Pedro Rui Neto de Abreu, President, Power Systems at PHINIA INC. (NYSE:PHIN), filed a Form 4 on September 21, 2026, reporting the acquisition of 22 shares of common stock on September 18, 2026, through automatic dividend reinvestment on outstanding equity awards.
Kecia Steelman, President and CEO of Ulta Beauty, Inc. (NASDAQ:ULTA), filed a Form 4 on September 21, 2026, disclosing the sale of 2,000 shares of common stock on September 17, 2026.
Patrick F. Williams, Chief Financial Officer of NeuroPace Inc, filed a Form 4 on September 21, 2026, disclosing the disposition of 1,162 shares of common stock on September 20, 2026, to satisfy tax withholding obligations connected to a vesting restricted stock unit award.
A Form 4 filed on September 21, 2026, reports that Bertram L. Scott, a director of Equitable Holdings, Inc. (NYSE:EQH), sold 2,780 shares of common stock on September 21, 2026.
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), filed a Form 4 on September 21, 2026, disclosing a stock option exercise and the sale of 6,018 shares of common stock on September 17, 2026, pursuant to a Rule 10b5-1 trading plan.
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., filed a Form 4 on September 21, 2026, reporting an option exercise and the sale of common stock on September 17, 2026, pursuant to a Rule 10b5-1 trading plan.
Please wait processing your request...